These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20461251)

  • 1. Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth.
    Huang PH; Miraldi ER; Xu AM; Kundukulam VA; Del Rosario AM; Flynn RA; Cavenee WK; Furnari FB; White FM
    Mol Biosyst; 2010 Jul; 6(7):1227-37. PubMed ID: 20461251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
    Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
    Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival.
    Zhan Y; O'Rourke DM
    Cancer Res; 2004 Nov; 64(22):8292-8. PubMed ID: 15548697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
    Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
    Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
    Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
    Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
    Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.
    Roos A; Dhruv HD; Peng S; Inge LJ; Tuncali S; Pineda M; Millard N; Mayo Z; Eschbacher JM; Loftus JC; Winkles JA; Tran NL
    Mol Cancer Res; 2018 Jul; 16(7):1185-1195. PubMed ID: 29724813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.
    Huang PH; Mukasa A; Bonavia R; Flynn RA; Brewer ZE; Cavenee WK; Furnari FB; White FM
    Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12867-72. PubMed ID: 17646646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR
    von Achenbach C; Silginer M; Blot V; Weiss WA; Weller M
    Mol Cancer Ther; 2020 Jun; 19(6):1328-1339. PubMed ID: 32371586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.
    Feng H; Hu B; Jarzynka MJ; Li Y; Keezer S; Johns TG; Tang CK; Hamilton RL; Vuori K; Nishikawa R; Sarkaria JN; Fenton T; Cheng T; Furnari FB; Cavenee WK; Cheng SY
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3018-23. PubMed ID: 22323579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
    Rong Y; Belozerov VE; Tucker-Burden C; Chen G; Durden DL; Olson JJ; Van Meir EG; Mackman N; Brat DJ
    Cancer Res; 2009 Mar; 69(6):2540-9. PubMed ID: 19276385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
    Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL
    Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor.
    Klingler-Hoffmann M; Fodero-Tavoletti MT; Mishima K; Narita Y; Cavenee WK; Furnari FB; Huang HJ; Tiganis T
    J Biol Chem; 2001 Dec; 276(49):46313-8. PubMed ID: 11514572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.
    Lo HW; Cao X; Zhu H; Ali-Osman F
    Mol Cancer Res; 2010 Feb; 8(2):232-45. PubMed ID: 20145033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
    Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
    Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear EGFRvIII resists hypoxic microenvironment induced apoptosis via recruiting ERK1/2 nuclear translocation.
    Xie H; Yang J; Xing W; Dong Y; Ren H
    Biochem Biophys Res Commun; 2016 Feb; 470(2):466-472. PubMed ID: 26742423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.
    Zhan Y; Counelis GJ; O'Rourke DM
    Exp Cell Res; 2009 Aug; 315(14):2343-57. PubMed ID: 19427850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse injurious stimuli reduce protein tyrosine phosphatase-μ expression and enhance epidermal growth factor receptor signaling in human airway epithelia.
    Hyun SW; Anglin IE; Liu A; Yang S; Sorkin JD; Lillehoj E; Tonks NK; Passaniti A; Goldblum SE
    Exp Lung Res; 2011 Aug; 37(6):327-43. PubMed ID: 21649524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.